ArticleEndocrine2026
Fear of cancer recurrence in papillary thyroid cancer: a comparison across ATA risk groups and influencing factors.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFear of cancer recurrence (FCR) is a common concern among papillary thyroid cancer (PTC) survivors and may not reflect actual recurrence risk. This study aimed to assess FCR in low-risk PTC patients compared to intermediate- and high-risk groups and to identify factors influencing FCR.
methodsA total of 240 patients were included in this cross-sectional study. Patients were classified into low, intermediate, and high risk, according to the American Thyroid Association (ATA) 2015 risk stratification system. All participants completed the Fear of Cancer Recurrence Inventory (FCRI) and the Beck Anxiety Inventory (BAI) questionnaires.
resultsAmong 240 patients, 132 (55%) were classified as ATA low-risk, 86 (36%) as intermediate-risk, and 22 (9%) as high-risk. FCRI scores were similar among ATA low-, intermediate-, and high-risk patients (p = 0.895). Patients with a disease duration of one to five years had higher FCRI scores compared to those with a disease duration of less than one year or more than five years (p = 0.03). A negative correlation was observed between age and FCRI score (r=-0.131, p = 0.043). In multivariable analysis, BAI score was positively associated with FCRI score (β = 1.33, p < 0.001). After adjustment for age, disease duration, and anxiety severity, FCRI scores remained similar across ATA risk groups (p = 0.978).
conclusionFCR levels in low-risk patients were comparable to those in intermediate- and high-risk groups. These findings suggest that factors beyond objective disease risk, including anxiety severity, younger age, and disease duration, may contribute to FCR, underscoring the need for appropriate psychosocial assessment and support.
Indexed as
Identifiers
42440008What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.